Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Metabolomics Technology Applied to Non-Invasive Nash Biomarkers Research
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Metabolon, Inc. announces a study published in the Metabolism Journal released in the paper on April 28, 2010, by Satish C. Kalhan.
Metabolon studied plasma profiles from subjects with nonalcoholic fatty liver disease (NAFLD). Using Metabolon’s patented global metabolomic profiling platform, the study, authored by Satish C. Kalhan and his collaborators at the Cleveland Clinic and Case Western Reserve University School of Medicine and with scientists from Metabolon, identified a panel of potential noninvasive biomarkers in NAFLD and Nonalcoholic Steatohepatitis (NASH). The results represent both a significant step in understanding the disease and for the development of therapeutic interventions.
Metabolon studied plasma profiles from subjects with nonalcoholic fatty liver disease (NAFLD). Using Metabolon’s patented global metabolomic profiling platform, the study, authored by Satish C. Kalhan and his collaborators at the Cleveland Clinic and Case Western Reserve University School of Medicine and with scientists from Metabolon, identified a panel of potential noninvasive biomarkers in NAFLD and Nonalcoholic Steatohepatitis (NASH). The results represent both a significant step in understanding the disease and for the development of therapeutic interventions.
